Singhania now said to Et, that Indian It, despite his worldwide strengths, is confronted with growth and structural challenges. “With growth by 3-5%, it is difficult to justify PE-Veevouden from 25-27. Moreover, global capacity centers reduce dependence on outsourcing, and AI is starting to have an impact in the short term,” he noticed. He added that although IT services remain under pressure, the interests of investors are shifting to New-Age Technology companies, including platform and D2C companies, although Abakkus remains loss-making companies due to the value-driven philosophy.
With broader assignments, Singhania remains optimistic about banks and financial services, although he warned against expecting the 18-20% credit growth of the past. “With GDP growth by 6.5-7%, credit growth of 10-11% is realistic. Investors must be satisfied with 14-15% returns of quality banks and NBFCs. Insurance, asset management and asset management also offer strong opportunities,” he said.
Capex and manufacture future growth motorcycles
He also pointed to consumption as an area of interest, although with a word of caution. “Piles have recently reduced 10-15%, but they still act on 50-70x PEs despite 2-5% growth. With GST reduction and income tax that adds liquidity, there will be an increase in consumption, but valuations remain a concern,” he noticed.
Looking ahead, Singhania Capex and production see as inevitable growth engines. “India cannot strive to be an economy of $ 7-10 trillion without production and Capex. Although export-oriented sectors can temporarily delay due to the global rate of uncertainties, long-term perspectives for capital goods and power are strong,” he said.
According to him, Farma also offers ‘decent opportunities’, especially with corrections. “It’s a good time for investors to build positions,” he added.
Singhania believes that market correction offers selective opportunities, but the return expectations must be moderated. “Investors must be in line with the center of a teenage return. Extraordinary return of 30-40% CAGR, as can be seen in 2020-24, will not repeat. In this area, discipline and valuation-conscious investing investment,” he said.
#Sunil #Singhania #warns #bets #financial #pharmaceutical #Capex #Revival

